Skip Navigation LinksHome > June 2012 - Volume 31 - Issue 6 > Trough Lopinavir Concentrations in Preterm HIV-infected Infa...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31825046ae
HIV Reports

Trough Lopinavir Concentrations in Preterm HIV-infected Infants

Holgate, Sandi L. FCPaed*; Rabie, Helena FCPaedMSc ID*; Smith, Peter PhD; Cotton, Mark F. FCPaed, PhD*,‡

Collapse Box

Abstract

Because of serious adverse effects, the Food and Drug Administration warns against using lopinavir in infants younger than 42 weeks postconception. However, there is an imperative for early treatment. We report on our use of LPV in 8 premature HIV-infected infants. The median age at initiation was 27 days. Trough values guided dosing. Five infants needed doses above 300 mg/m2. Although no adverse events were noted, lopinavir usage requires caution and careful monitoring.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.